Cargando…

Management of transfusional iron overload – differential properties and efficacy of iron chelating agents

Regular red cell transfusion therapy ameliorates disease-related morbidity and can be lifesaving in patients with various hematological disorders. Transfusion therapy, however, causes progressive iron loading, which, if untreated, results in endocrinopathies, cardiac arrhythmias and congestive heart...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kwiatkowski, Janet L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262345/ https://www.ncbi.nlm.nih.gov/pubmed/22287873 http://dx.doi.org/10.2147/JBM.S13065

Ejemplares similares

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation
por: Stanley, Helen M., et al.
Publicado: (2016)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes
por: Petrou, Emmanouil, et al.
Publicado: (2015)

Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron
por: La Carpia, Francesca, et al.
Publicado: (2019)

PB2565: TRANSFUSIONAL IRON OVERLOAD AND ASSOCIATED COMPLICATIONS IN HEMATOLOGY DISORDERS PATIENTS
por: Romanenko, Nikolay, et al.
Publicado: (2023)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach
por: Islam, Sufia, et al.
Publicado: (2022)

Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict
por: Touma, Hanan, et al.
Publicado: (2023)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats
por: Wongjaikam, Suwakon, et al.
Publicado: (2016)

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children
por: Lee, J W, et al.
Publicado: (2009)

In vivo calibration of the T2* cardiovascular magnetic resonance method at 1.5 T for estimation of cardiac iron in a minipig model of transfusional iron overload
por: Jensen, Peter Diedrich, et al.
Publicado: (2021)

Iron-Chelating Agent Can Maintain Bone Homeostasis Disrupted by Iron Overload by Upregulating Wnt/Beta-Catenin Signaling
por: Xu, Wei, et al.
Publicado: (2020)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
por: Ghosh, Kanjaksha, et al.
Publicado: (2018)

Iron chelation effect of curcumin and baicalein on aplastic anemia mouse model with iron overload
por: Dijiong, Wu, et al.
Publicado: (2019)

Erythrocytapheresis in Children and Young Adults with Hemoglobinopathies and Iron Overload in Need of Iron Chelation Therapy
por: van Hattem, Jessica, et al.
Publicado: (2023)

Management of Iron Overload in Resource Poor Nations: A Systematic Review of Phlebotomy and Natural Chelators
por: Orisakwe, Orish Ebere, et al.
Publicado: (2020)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature
por: Belmouhand, Mohamed, et al.
Publicado: (2021)

Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review
por: Romadhon, Pradana Zaky, et al.
Publicado: (2022)

Comparison Between Hesperidin, Coumarin, and Deferoxamine Iron Chelation and Antioxidant Activity Against Excessive Iron in the Iron Overloaded Mice
por: Aalikhani, Mahdi, et al.
Publicado: (2022)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Naringin Chelates Excessive Iron and Prevents the Formation of Amyloid-Beta Plaques in the Hippocampus of Iron-Overloaded Mice
por: Jahanshahi, Mehrdad, et al.
Publicado: (2021)

Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers
por: Hruby, Martin, et al.
Publicado: (2021)

The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the Brain
por: Crichton, Robert R., et al.
Publicado: (2019)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Harnessing microbial iron chelators to develop innovative therapeutic agents
por: Ribeiro, Marta, et al.
Publicado: (2021)

Iron overload disorders
por: Hsu, Christine C., et al.
Publicado: (2022)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_64o69lmtc6i2oai9nqujnk2t23